You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.
With targeted sequence data on more than 500 cases of the lymphatic fluid accumulation condition, researchers found and explored lymphedema-related ANGPT2 mutations.
Two new papers have identified thousands of genetic loci with ties to more than two-dozen blood cell traits in individuals from up to five ancestry groups.
Under the agreement, Israel’s BiomX will generate metagenomic data for gut microbiome samples from IBD patients using its XMarker biomarker discovery platform.
Todos also announced a $23.8 million sales agreement this week with an unnamed Wisconsin laboratory covering testing equipment and supplies.
An analysis of whole-exome sequencing, brain gene expression, and health data suggests an autism subtype marked by dyslipidemia.
In PNAS this week: Zika virus mutation linked to increased transmission, variants associated with inherited hearing loss, and more.
News items for the week of July 27, 2020.
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
In Genome Research this week: approach to determine lncRNA function, transcriptome pattern across vertebrate cells, and more.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.